AbbVie's Rinvoq Meets Main Phase 3 Endpoints in Psoriatic Arthritis
February 05 2020 - 9:27AM
Dow Jones News
By Colin Kellaher
AbbVie Inc. (ABBV) Wednesday said Rinvoq met the primary and key
secondary endpoints in a phase 3 study in psoriatic arthritis.
The North Chicago, Ill., biopharmaceutical company said the 15-
and 30-milligram once-daily doses of Rinvoq met the primary
endpoint of ACR20 response at week 12 versus placebo in adults with
active psoriatic arthritis.
Rinvoq also showed significant improvements in signs and
symptoms of the inflammatory disease across a variety of endpoints
compared to placebo, the company said.
AbbVie said it will share the data with regulatory bodies around
the world to support its application for expanded use of the drug,
which last year received U.S. and European approval for adults with
moderately to severely active rheumatoid arthritis.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 05, 2020 09:12 ET (14:12 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Mar 2024 to Apr 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Apr 2023 to Apr 2024
